HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

pateclizumab

Also Known As:

MLTA-3698A; MLTA3698A; PRO-283698; PRO283698; RG-7415; RG-7416; RG7415

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Xiao, Jim: 2 articles (01/2016 - 01/2012)
2.	Davis, John C: 2 articles (10/2014 - 01/2012)
3.	Grogan, Jane L: 2 articles (10/2014 - 01/2012)
4.	Offutt, Carolyn: 2 articles (10/2014 - 01/2012)
5.	Tang, Meina T: 2 articles (10/2014 - 01/2012)
6.	Arima, Akihiro: 1 article (01/2016)
7.	Cain, Gary: 1 article (01/2016)
8.	Chihaya, Yutaka: 1 article (01/2016)
9.	Gelzleichter, Thomas: 1 article (01/2016)
10.	Grogan, Jane: 1 article (01/2016)

Related Diseases

1.	Rheumatoid Arthritis 10/30/2014 - "Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)." 01/08/2012 - "Pateclizumab (MLTA3698A) is a humanized mAb against lymphotoxin α (LTα), a transiently expressed cytokine on activated B and T cells (Th1, Th17), which are implicated in rheumatoid arthritis (RA) pathogenesis. "
2.	Infections 10/30/2014 - "Serious AEs occurred in 0% of pateclizumab, 5.9% of adalimumab, and 2.3% of placebo patients, with serious infection in 2.3% of adalimumab patients and none in pateclizumab and placebo patients. "
3.	Body Weight (Weight, Body) 01/01/2016 - "Decreased fetal inguinal lymph node-to-body weight ratio was present in the high-dose group without microscopic abnormalities, a change attributable to inhibition of lymphocyte recruitment, which is a pharmacologic effect of pateclizumab during late lymph node development. "

Related Drugs and Biologics

1.	Lymphotoxin-alpha (Lymphotoxin)
2.	Adalimumab (Humira)
3.	pateclizumab
4.	Cytokines